Patient characteristics (n = 26)
| Mean age (range, y) | 49.3 (23-77) |
| Sex, n (%) | |
| Male | 18 (69) |
| Female | 8 (31) |
| Disease subtype, n (%) | |
| ECD | 17 (65) |
| RDD | 3 (12) |
| ECD/RDD | 5 (20) |
| ECD/LCH | 1 (3) |
| Genotype | |
| BRAFV600E mutation | 9 |
| Other BRAF alteration (including fusion) | 4 |
| MAP2K1 alteration | 6 |
| NRAS alteration | 2 |
| KRAS alteration | 2 |
| ASXL1 alteration | 3 |
| NF1 alteration | 3 |
| MCL1 amplification | 1 |
| RB1 alteration | 1 |
| ERBB2 amplification | 1 |
| RAF1 amplification | 1 |
| APC alteration | 1 |
| CCNE1 alteration | 1 |
| IDH2 alteration | 1 |
| No mutations identified (either BRAF wild-type, not sequenced, or mutation-negative) | 4 |
| Median number of lines of prior therapy (range) | 2 (1-4) |
| Mean age (range, y) | 49.3 (23-77) |
| Sex, n (%) | |
| Male | 18 (69) |
| Female | 8 (31) |
| Disease subtype, n (%) | |
| ECD | 17 (65) |
| RDD | 3 (12) |
| ECD/RDD | 5 (20) |
| ECD/LCH | 1 (3) |
| Genotype | |
| BRAFV600E mutation | 9 |
| Other BRAF alteration (including fusion) | 4 |
| MAP2K1 alteration | 6 |
| NRAS alteration | 2 |
| KRAS alteration | 2 |
| ASXL1 alteration | 3 |
| NF1 alteration | 3 |
| MCL1 amplification | 1 |
| RB1 alteration | 1 |
| ERBB2 amplification | 1 |
| RAF1 amplification | 1 |
| APC alteration | 1 |
| CCNE1 alteration | 1 |
| IDH2 alteration | 1 |
| No mutations identified (either BRAF wild-type, not sequenced, or mutation-negative) | 4 |
| Median number of lines of prior therapy (range) | 2 (1-4) |